New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:56 EDTNWBONorthwest Bio press releases called 'inappropriate,' The Street reports
Dr. Aman Buzdar of MD Anderson Cancer Center, which is running the running the DCVax-Direct phase I/II clinical trial with funding from Northwest Biotherapeutics (NWBO), called the company's press releases "extremely unusual and inappropriate," The Street's Adam Feuerstein reports, citing a phone interview. Buzdar said MD Anderson and the two other hospitals conducting the DCVAX-Direct study are yet to review or analyze the trial data since patients are still being enrolled and treated. Shares of Northwest are trading down 10% to $8.11 in pre-open trading. Reference Link
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTNWBONorthwest Biotherapeutics begins first treatment with DCVax-L in Germany
Subscribe for More Information
October 7, 2014
09:07 EDTNWBONorthwest Biotherapeutics raises $11.5M through an institutional stock sale
Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
09:05 EDTNWBONorthwest Biotherapeutics enters into $11.5M financing agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use